ArticleBioinformatics (Oxford, England)2019
PRECISE: a domain adaptation approach to transfer predictors of drug response from pre-clinical models to tumors.
Article in Bioinformatics (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Methodological challenges in translational drug response modeling in cancer: A systematic analysis with FORESEE.PLoS computational biology · 2020Pooled it
- Systems biology framework for the rational design of operational conditions for in vitro/in vivo translation of tissue models.Science advances · 2026Article
- TMEDRP: decoding tumor-intrinsic and microenvironmental signatures for clinical drug response prediction.Bioinformatics (Oxford, England) · 2026Article
- Deep Unsupervised Domain Adaptation for Translating Cancer Dependency Maps From Cell Lines to Breast Cancer Tumor Genomics.Genetic epidemiology · 2026Article
- Zero-shot reconstruction of mutant spatial transcriptomes.Patterns (New York, N.Y.) · 2026Article
- MDCDR: predicting cancer drug response via multimodal feature fusion and feature disentanglement.Briefings in bioinformatics · 2026Article
- Discovery of predictive biomarkers for cancer therapy through computational approaches.Nature reviews. Clinical oncology · 2026Review
- SpaGene: A Deep Adversarial Framework for Spatial Gene Imputation.Computational and structural biotechnology journal · 2026Article
- SpaGene: A Deep Adversarial Framework for Spatial Gene Imputation.bioRxiv : the preprint server for biology · 2025Article
- A disentangled generative model for improved drug response prediction in patients via sample synthesis.Journal of pharmaceutical analysis · 2025Article
- Out of distribution learning in bioinformatics: advancements and challenges.Briefings in bioinformatics · 2025Review
- A multi-task domain-adapted model to predict chemotherapy response from mutations in recurrently altered cancer genes.iScience · 2025Article
- KSRV: a Kernel PCA-Based framework for inferring spatial RNA velocity at single-cell resolution.Frontiers in genetics · 2025Article
- Gene signature for response prediction to immunotherapy and prognostic markers in metastatic urothelial carcinoma.Frontiers in immunology · 2025Article
- Application of Spatial Transcriptomics in Digestive System Tumors.Biomolecules · 2024Review
- Domain adaptation in small-scale and heterogeneous biological datasets.Science advances · 2024Review
- SIRV: spatial inference of RNA velocity at the single-cell resolution.NAR genomics and bioinformatics · 2024Article
- Pan-Cancer Drug Response Prediction Using Integrative Principal Component Regression.Statistics in biosciences · 2024Article
- Machine learning integrative approaches to advance computational immunology.Genome medicine · 2024Review
- PrCRS: a prediction model of severe CRS in CAR-T therapy based on transfer learning.BMC bioinformatics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
motivationCell lines and patient-derived xenografts (PDXs) have been used extensively to understand the molecular underpinnings of cancer. While core biological processes are typically conserved, these models also show important differences compared to human tumors, hampering the translation of findings from pre-clinical models to the human setting. In particular, employing drug response predictors generated on data derived from pre-clinical models to predict patient response remains a challenging task. As very large drug response datasets have been collected for pre-clinical models, and patient drug response data are often lacking, there is an urgent need for methods that efficiently transfer drug response predictors from pre-clinical models to the human setting.
resultsWe show that cell lines and PDXs share common characteristics and processes with human tumors. We quantify this similarity and show that a regression model cannot simply be trained on cell lines or PDXs and then applied on tumors. We developed PRECISE, a novel methodology based on domain adaptation that captures the common information shared amongst pre-clinical models and human tumors in a consensus representation. Employing this representation, we train predictors of drug response on pre-clinical data and apply these predictors to stratify human tumors. We show that the resulting domain-invariant predictors show a small reduction in predictive performance in the pre-clinical domain but, importantly, reliably recover known associations between independent biomarkers and their companion drugs on human tumors. AVAILABILITY AND IMPLEMENTATION: PRECISE and the scripts for running our experiments are available on our GitHub page (https://github.com/NKI-CCB/PRECISE). SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.